Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2025
0mins
Source: Globenewswire
NXP900 Clinical Trial Update: The Phase 1a dose-escalation study of NXP900 showed robust pharmacodynamic responses and an acceptable safety profile, with no identified dose-limiting toxicity up to 250 mg/day. Preliminary clinical data supports its potential use in biomarker-targeted cancers and in combination therapies for non-small cell lung cancer (NSCLC).
Future Development Plans: Nuvectis Pharma plans to initiate a Phase 1b program focusing on patients with advanced cancers that have YES1 gene amplifications and Hippo pathway alterations, as well as evaluating NXP900 in combination with leading therapies to address treatment resistance in NSCLC.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
